PGS Publication: PGP000114

Publication Information (EuropePMC)
Title Risk prediction for coronary heart disease by a genetic risk score - results from the Heinz Nixdorf Recall study.
PubMed ID 32912153(Europe PMC)
doi 10.1186/s12881-020-01113-y
Publication Date Sept. 10, 2020
Journal BMC Med Genet
Author(s) Pechlivanis S, Lehmann N, Hoffmann P, Nöthen MM, Jöckel KH, Erbel R, Moebus S.
Released in PGS Catalog: Dec. 8, 2020

Associated Polygenic Score(s)

PGS Developed By This Publication

Polygenic Score (PGS) ID PGS Name PGS Publication (PGP) ID Reported Trait Mapped Trait(s) (Ontology) Number of Variants PGS Scoring File (FTP Link)
PGS000349 PRS70_CAD PGP000114 Pechlivanis S et al. BMC Med Genet (2020) Coronary artery disease coronary artery disease 70 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000349/ScoringFiles/PGS000349.txt.gz

PGS Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance Metric ID
(PPM ID)
Evaluated Score PGS Sample Set ID
(PSS ID)
Performance Source Trait PGS Effect Sizes
(per SD change)
PGS Classification Metrics Other Metrics Covariates Included in the Model PGS Performance: Other Relevant Information
PPM000996 PGS000349 (PRS70_CAD) PSS000508 PGP000114
Pechlivanis S et al. (2020)
Reported Trait: Coronary artery calcification OR: 1.19 [1.1, 1.29] age, sex, cardiovascular risk factors (systolic blood pressure, antihypertensive medication, smoking, LDL-cholestrol, HDL-cholesterol, lipid lowering medication, BMI and diabetes).
PPM000995 PGS000349 (PRS70_CAD) PSS000505 PGP000114
Pechlivanis S et al. (2020)
Reported Trait: Coronary artery calcification OR: 1.18 [1.1, 1.27] age, sex, cardiovascular risk factors (systolic blood pressure, antihypertensive medication, smoking, LDL-cholestrol, HDL-cholesterol, lipid lowering medication, BMI and diabetes).
PPM000993 PGS000349 (PRS70_CAD) PSS000509 PGP000114
Pechlivanis S et al. (2020)
Reported Trait: Incident Coronary Heart Disease in indiviuals with coronary artery calcification > 0 HR: 1.21 [1.08, 1.36] age, sex, cardiovascular risk factors (systolic blood pressure, antihypertensive medication, smoking, LDL-cholestrol, HDL-cholesterol, lipid lowering medication, BMI and diabetes).
PPM000992 PGS000349 (PRS70_CAD) PSS000510 PGP000114
Pechlivanis S et al. (2020)
Reported Trait: Incident Coronary Heart Disease in males HR: 1.23 [1.07, 1.41] age, cardiovascular risk factors (systolic blood pressure, antihypertensive medication, smoking, LDL-cholestrol, HDL-cholesterol, lipid lowering medication, BMI and diabetes) and coronary artery calcification.
PPM000991 PGS000349 (PRS70_CAD) PSS000506 PGP000114
Pechlivanis S et al. (2020)
Reported Trait: Incident Coronary Heart Disease in males HR: 1.25 [1.1, 1.42] age
PPM000990 PGS000349 (PRS70_CAD) PSS000507 PGP000114
Pechlivanis S et al. (2020)
Reported Trait: Incident Coronary Heart Disease HR: 1.18 [1.06, 1.31] age, sex, cardiovascular risk factors (systolic blood pressure, antihypertensive medication, smoking, LDL-cholestrol, HDL-cholesterol, lipid lowering medication, BMI and diabetes) and coronary artery calcification.
PPM000989 PGS000349 (PRS70_CAD) PSS000504 PGP000114
Pechlivanis S et al. (2020)
Reported Trait: Incident Coronary Heart Disease HR: 1.18 [1.06, 1.31] age, sex
PPM000994 PGS000349 (PRS70_CAD) PSS000511 PGP000114
Pechlivanis S et al. (2020)
Reported Trait: Incident Coronary Heart Disease in males with coronary artery calcification > 0 HR: 1.26 [1.09, 1.46] age, cardiovascular risk factors (systolic blood pressure, antihypertensive medication, smoking, LDL-cholestrol, HDL-cholesterol, lipid lowering medication, BMI and diabetes).

Evaluated Samples

PGS Sample Set ID
(PSS ID)
Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000504 Participants with no prior Coronary Heart Disease (CHD) at the time of enrollment were included within the present study. Incidental CHD was the primary end-points of the study. CHD was defined as fatal and non-fatal myocardial infarction, stroke and coronary death. Median = 11.6 years
Sd = 3.7 years
[
  • 343 cases
  • , 3,698 controls
]
,
47.5 % Male samples
Mean = 58.9 years
Sd = 7.6 years
European HNR
PSS000505
[
  • 2,734 cases
  • , 1,307 controls
]
European HNR
PSS000506 Male participants with no prior Coronary Heart Disease (CHD) at the time of enrollment were included within the present study. Incidental CHD was the primary end-points of the study. CHD was defined as fatal and non-fatal myocardial infarction, stroke and coronary death.
[
  • 219 cases
  • , 1,700 controls
]
,
100.0 % Male samples
European HNR
PSS000507 Participants with no prior Coronary Heart Disease (CHD) at the time of enrollment were included within the present study. Incidental CHD was the primary end-points of the study. CHD was defined as fatal and non-fatal myocardial infarction, stroke and coronary death. Cardiovascular risk factor data required included smoking status, current use of medication, body mass index, levels of serum triglycerides, low densitity lipoprotein-cholesterol and high densitity lipoprotein-cholesterol and diabetes defined as either of 4 criteria (1) participants reported a history of clinically diagnosed diabetes, (2) participants took glucose-lowering medications, (3) participants had fasting glucose levels of greater than 125mg/dL or (4) participants had non-fasting glucose levels of 200mg/dL or greater.
[
  • 321 cases
  • , 3,427 controls
]
European HNR
PSS000508
[
  • 2,536 cases
  • , 1,212 controls
]
European HNR
PSS000509 Participants with no prior Coronary Heart Disease (CHD) at the time of enrollment with coronary artery calcification>0 were included. Incidental CHD was the primary end-points of the study. CHD was defined as fatal and non-fatal myocardial infarction, stroke and coronary death. Cardiovascular risk factor data required included smoking status, current use of medication, body mass index, levels of serum triglycerides, low densitity lipoprotein-cholesterol and high densitity lipoprotein-cholesterol and diabetes defined as either of 4 criteria (1) participants reported a history of clinically diagnosed diabetes, (2) participants took glucose-lowering medications, (3) participants had fasting glucose levels of greater than 125mg/dL or (4) participants had non-fasting glucose levels of 200mg/dL or greater.
[
  • 278 cases
  • , 2,282 controls
]
European HNR
PSS000510 Male participants with no prior Coronary Heart Disease (CHD) at the time of enrollment were included within the present study. Incidental CHD was the primary end-points of the study. CHD was defined as fatal and non-fatal myocardial infarction, stroke and coronary death. Cardiovascular risk factor data required included smoking status, current use of medication, body mass index, levels of serum triglycerides, low densitity lipoprotein-cholesterol and high densitity lipoprotein-cholesterol and diabetes defined as either of 4 criteria (1) participants reported a history of clinically diagnosed diabetes, (2) participants took glucose-lowering medications, (3) participants had fasting glucose levels of greater than 125mg/dL or (4) participants had non-fasting glucose levels of 200mg/dL or greater.
[
  • 202 cases
  • , 1,563 controls
]
,
100.0 % Male samples
European HNR
PSS000511 Male participants with no prior Coronary Heart Disease (CHD) at the time of enrollment with coronary artery calcification>0 were included. Incidental CHD was the primary end-points of the study. CHD was defined as fatal and non-fatal myocardial infarction, stroke and coronary death. Cardiovascular risk factor data required included smoking status, current use of medication, body mass index, levels of serum triglycerides, low densitity lipoprotein-cholesterol and high densitity lipoprotein-cholesterol and diabetes defined as either of 4 criteria (1) participants reported a history of clinically diagnosed diabetes, (2) participants took glucose-lowering medications, (3) participants had fasting glucose levels of greater than 125mg/dL or (4) participants had non-fasting glucose levels of 200mg/dL or greater.
[
  • 186 cases
  • , 1,240 controls
]
,
100.0 % Male samples
European HNR